SLC5A2 and chronic kidney disease: Dedicated kidney outcome randomised controlled trials (RCT) (CREDENCE, DAPA-CKD, and EMPA-KIDNEY) reported reduced rates in composite renal outcomes, which was defined as the doubling of serum creatinine, end-stage renal disease or renal death in patients treated with SGLT2-i [16,17,18].